ASMB · Assembly Biosciences, Inc.

Assembly Biosciences reported its first quarter 2026 financial results, highlighting steady progress across its viral disease portfolio. The company completed Phase 1b studies for its helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes, reinforcing confidence in safety and efficacy. Additionally, chronic toxicology studies for ABI-6250, an oral entry inhibitor for chronic hepatitis delta virus (HDV), were completed, supporting an anticipated Phase 2 initiation in Q4 2026. Collaboration revenue from Gilead decreased to $8.2 million from $9.4 million in the prior year quarter, reflecting the timing of activities under the collaboration. Research and development expenses remained consistent at $14.9 million, while general and administrative expenses increased slightly to $4.7 million due to stock-based compensation. Net loss was $9.1 million, or $0.54 per share, compared to $8.8 million, or $1.17 per share, in the same period last year, with the per-share improvement driven by a higher weighted-average share count. The company ended the quarter with $226.6 million in cash, cash equivalents, and marketable securities, projected to fund operations into 2028. Management highlighted upcoming milestones, including receipt of Gilead's development plan for the HPI program by mid-2026, which will inform a potential opt-in to a 40% U.S. cost-profit share. The company also presented data at the ESCMID congress and plans to attend the EASL Congress in May 2026.